ContraFect Corp
Company Profile
Business description
ContraFect Corp is a late clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections. Its DLA product candidate, exebacase, is currently being studied in patients with chronic prosthetic joint infections (PJIs) of the knee due to S. aureus or coagulase-negative Staphylococci, and the next product candidate, CF-370, is designed to target a range of gram-negative bacteria, including P. aeruginosa, K. pneumoniae, and A. baumannii, and has demonstrated potent in vivo activity against these pathogens, even against multidrug-resistant (MDR) and extensively drug-resistant (XDR) strains.
Contact
28 Wells Avenue
3rd Floor
YonkersNY10701
USAT: +1 914 207-2300
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
23
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
---|---|---|---|
All Ordinaries | 8,462.60 | 40.90 | 0.49% |
CAC 40 | 7,743.75 | 49.31 | 0.64% |
DAX 40 | 23,499.32 | 146.63 | 0.63% |
Dow JONES (US) | 41,249.38 | 119.07 | -0.29% |
FTSE 100 | 8,554.80 | 23.19 | 0.27% |
HKSE | 22,867.74 | 91.82 | 0.40% |
NASDAQ | 17,928.92 | 0.78 | 0.00% |
Nikkei 225 | 37,503.33 | 574.70 | 1.56% |
NZX 50 Index | 12,605.07 | 138.04 | 1.11% |
S&P 500 | 5,659.91 | 4.03 | -0.07% |
S&P/ASX 200 | 8,231.20 | 39.50 | 0.48% |
SSE Composite Index | 3,342.00 | 10.00 | -0.30% |